Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTILIV: Cetuximab + HAI Triplet for Liver Metastases
NCT00852228Phase 2Unknown
- Sponsor
- Association pour la Recherche sur le Temps Biologique et la Chronothérapie
- Start
- Jul 2008
- Primary completion
- Mar 2012
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 4
01
Overview
A Phase 2 trial of KL-140, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, oxaliplatin, fluorouracil in colorectal cancer (CRC), sponsored by Association pour la Recherche sur le Temps Biologique et la Chronothérapie. Status: unknown.
02
Drugs
KL-140irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatinfluorouracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00852228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00852228.